Active Ingredient: Belzutifan
Belzutifan is indicated for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
For this indication, competent medicine agencies globally authorize below treatments:
For:
Oral, 120 milligrams belzutifan, once daily.
The recommended dosage is 120 mg administered orally once daily until disease progression or unacceptable toxicity.
If a dose of belzutifan is missed, it can be taken as soon as possible on the same day. Resume the regular daily dose schedule for belzutifan the next day. Do not take extra tablets to make up for the missed dose.
If vomiting occurs any time after taking belzutifan, do not retake the dose. Take the next dose on the next day.
Dosage modifications for belzutifan for adverse reactions are summarized in the table below.
The recommended dose reductions are:
Recommended dosage modifications for adverse reactions:
| Adverse Reaction | Severity | Dosage Modification |
|---|---|---|
| Anemia | Hemoglobin <8 g/dL or transfusion indicated | • Withhold until hemoglobin ≥8g/dL. • Resume at the same or reduced dose; or discontinue depending on the severity of anemia. |
| Life-threatening or urgent intervention indicated | • Withhold until hemoglobin ≥8g/dL. • Resume at a reduced dose or permanently discontinue. | |
| Hypoxia | Decreased oxygen saturation with exercise (e.g., pulse oximeter <88%) | • Consider withholding until resolved. • Resume at the same dose or at a reduced dose depending on the severity of hypoxia. |
| Decreased oxygen saturation at rest (e.g., pulse oximeter <88% or PaO2 ≤55 mm Hg) or urgent intervention indicated | • Withhold until resolved. • Resume at reduced dose or discontinue depending on the severity of hypoxia. | |
| Life-threatening or recurrent symptomatic hypoxia | • Permanently discontinue. | |
| Other Adverse Reactions | Grade 3 | • Withhold dosing until resolved to ≤ Grade 2. • Consider resuming at a reduced dose (reduce by 40 mg). • Permanently discontinue upon recurrence of Grade 3. |
| Grade 4 | • Permanently discontinue. |
Belzutifan should be taken at the same time each day and may be taken with or without food.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
